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Background: Genome-wide association studies have identified many genetic loci associated with blood pressure
(BP). Genetic effects on BP can be altered by environmental exposures via multiple biological pathways. Especially,
obesity is one of important environmental risk factors that can have considerable effect on BP and it may interact
with genetic factors. Given that, we aimed to test whether genetic factors and obesity may jointly influence BP.
Methods: We performed meta-analyses of genome-wide association data for systolic blood pressure (SBP) and
diastolic blood pressure (DBP) that included analyses of interaction between single nucleotide polymorphisms
(SNPs) and the obesity-related anthropometric measures, body mass index (BMI), height, weight, and waist/hip
ratio (WHR) in East-Asians (n = 12,030).
Results: We identified that rs13390641 on 2q12.1 demonstrated significant association with SBP when the
interaction between SNPs and BMI was considered (P < 5 × 10 −8). The gene located nearest to rs13390641,
TMEM182, encodes transmembrane protein 182. In stratified analyses, the effect of rs13390641 on BP was much
stronger in obese individuals (BMI ≥ 30) than non-obese individuals and the effect of BMI on BP was strongest
in individuals with the homozygous A allele of rs13390641.
Conclusions: Our analyses that included interactions between SNPs and environmental factors identified a genetic
variant associated with BP that was overlooked in standard analyses in which only genetic factors were included.
This result also revealed a potential mechanism that integrates genetic factors and obesity related traits in the
development of high BP.
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High blood pressure (BP) is one of the most common
diseases worldwide and is an important risk factor for
cardiovascular and renal disease [1,2]. Homeostasis of
blood volume, blood vessel resistance and blood thick-
ness are important for regulation of arterial pressure and
these are maintained by complex interactions of several* Correspondence: kbj6181@cdc.go.kr
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unless otherwise stated.physiological pathways, including hormonal responses,
nervous system signaling and intracellular feedback
[3,4]. Variation in BP also reflects genetic factors with
heritability ranging from 30 to 60% [5,6]. Large numbers
of genetic variants associated with BP and hypertension
have been identified in genome-wide association studies
(GWASs) [7-11], but these common variants (minor allele
frequency > 5%) with relatively small individual effect sizes
for BP cannot fully explain the phenotypic variance [7].
To account for much of the heritability of complex traits,
greater emphasis is being placed in recent years on
gene-environment interaction analyses [12]. Interactions. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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lying the biological network can potentially elucidate at
least part of the missing heritability [13].
High BP develops from a complex interplay of genetic
susceptibility factors and environmental factors [14]. A
variety of environmental factors have been shown to influ-
ence BP, including obesity, physical inactivity, alcohol
intake, tobacco use, and diet [1,3]. Obesity, in particular, is
a main cause of high BP because it induces sympathoacti-
vation that may raise BP [15].
To better understand the interactions between genes
and environmental risk factors for BP, some candidate
gene searches and few GWASs have included gene-
environment interaction terms [16-18]. By using this
method in GWAS, incorporation of genetic variations and
environmental risk factors may yield additional novel
loci that would not appear from analyses based on
genetic effect only.
To examine this hypothesis in our study, we performed
meta-analyses of GWASs for BP that included interactions
between single nucleotide polymorphisms (SNPs) and
the obesity-related anthropometric measures of body
mass index (BMI), height, weight, and waist-hip ratio
(WHR) using 12,030 East-Asians.
Methods
Study subjects
For our discovery stage and replication stage 1 study
subjects were enlisted from those enrolled in the Korean
Genome Epidemiology Study (KoGES) population-based
cohort. We selected 7,486 subjects from the Korea Associ-
ation REsource (KARE) project of KoGES [11] for the dis-
covery stage and 3,703 subjects from the Health Examinee
(HEXA) cohort [19] for replication stage 1. KARE project
included the initial subjects composed of 10,038 individ-
uals, aged 40 to 69, who were recruited from the Ansung
and the Ansan regional cohorts that located in Gyeonggi
province, near Seoul, the capital of Korea. Among them,
only study subjects who had not been treated for hy-
pertension, thyroid gland disease, osteoporosis, or asthma
and who had not taken steroids, oral contraceptives,
female sex hormone, or diuretics were included in the
baseline for the discovery stage. Subjects of HEXA cohort
were randomly selected from 1,200,000 participants of
KoGES, aged 40 to 69, for use as a shared control in
genome-wide disease association studies. More detailed
explanations of both cohorts were previously described
[11,19]. All subjects provided written informed consent and
this study was approved by ethical committee of the ins-
titute (Korea Centers for Disease Control and Prevention
Institutional Review Board).
To validate selected SNPs identified in the discovery
and replication stage 1, we performed analyses in repli-
cation stage 2 using data collected from a total of 841subjects enrolled in two independent studies of Japanese
populations, the Amagasaki and Ehime studies, descri-
bed previously [8].
Phenotype determination
In discovery stage and replication stage 1, BP measure-
ments were conducted using a standard mercury sphygmo-
manometer after the subjects had been in a sitting position
for at least 5 min. In case of replication stage 2, BP was
measured by automatic cuff-oscillometric device. The aver-
age of two measurements (left and right arm) was taken as
the BP. The average of SBPs and DBPs of discovery stage,
replication stage 1 and 2 are summarized in Table 1.
The obesity-related anthropometric measures BMI,
height, weight and WHR, were used in this study as envir-
onmental risk factors for elevated BP. BMI was defined as
weight in kg divided by the square of height in m. WHR
was defined as the ratio of waist (cm) to hip (cm) cir-
cumferences. In replication stage 2, only 3 of 4 anthropo-
metric measures were available, BMI, height, weight
except WHR.
Genotyping and quality control
All of the 10,004 KARE study samples were genotyped
using the Affymetrix Genome-Wide Human SNP array
5.0. After quality control, 8,842 subjects and 352,228
SNPs remained for analyses. For in silico replication, 4,302
individuals from the HEXA cohort were genotyped using
the Affymetrix Genome-Wide Human SNP array 6.0.
After quality control, 3,703 samples and 646,062 SNPs
remained. Genotype calling methods and quality control
criteria for samples and SNPs of both cohorts have been
previously described [11,19].
SNP imputation was conducted using the IMPUTE
program [20] based on International HapMap (phase 2,
release 22, NCBI build 36 and dbSNP build 126; http://
hapmap.ncbi.nlm.nih.gov/) data from JPT and CHB pop-
ulations. We used 1,573,409 SNPs for the KARE study
and 1,984,393 SNPs for the HEXA cohort after excluding
imputed SNPs of unsatisfactory quality for genetic ana-
lyses [19].
The results for replication stage 2 were generated from
356 individuals from the Ehime study using the Illumina
Human Omni 2.5-8 BeadChip and 485 individuals from
the Amagasaki study using the Illumina HumanHap
550 k Quad BeadChip.
Statistical analyses
Standardized residuals of SBP and DBP adjusted for
age and sex by linear regression were used as the
phenotypes for analyses in each study. To investigate
the effect of interaction between SNPs and the anthropo-
metric measures for BP, we conducted linear regression
analyses with interaction terms based on the equation:
Table 1 Descriptive statistics of study samples
Traits Discovery Replication 1 Replication 2 *P
KARE (n = 7,486) HEXA (n = 3,703) Ehime (n = 356) Amagasaki (n = 485)
Age 51.4 ± 8.77 53.2 ± 8.33 61.3 ± 11.2 61.6 ± 6.97 < 0.0001
Gender male (%) 3744 (50.0%) 1651 (44.6%) 126 (35.4%) 260 (53.6%) -
female (%) 3742 (50.0%) 2052 (55.4%) 230 (64.6%) 225 (46.3%) -
Blood pressure SBP (mmHg) 119.6 ± 17.4 121.7 ± 14.4 129.2 ± 19.7 128.4 ± 20.8 < 0.0001
DBP (mmHg) 79.3 ± 11.1 77.1 ± 9.89 74.8 ± 11.0 77.2 ± 11.8 < 0.0001
Anthropometric measures Height (cm) 160.5 ± 8.62 161.5 ± 8.10 158.0 ± 8.52 160.1 ± 7.97 < 0.0001
Weight (kg) 63.0 ± 10.1 62.6 ± 9.97 56.8 ± 10.6 59.5 ± 10.2 0.076
BMI (kg/m2) 24.4 ± 3.07 24.0 ± 2.90 22.6 ± 2.96 23.1 ± 3.13 < 0.0001
WHR 0.88 ± 0.07 0.86 ± 0.07 - - < 0.0001
n, sample size; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; WHR, waist-hip ratio.
KARE, Korean Association Resource Project; HEXA, Health Examinee cohort.
Data are shown as mean ± standard deviation. *P values were analyzed by t-test between the two groups, KARE and HEXA.
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height, weight, WHR) + β3 × (SNP × anthropometric mea-
sures). Y is the residual of SBP or DBP, β0 is a constant, β1
and β2 are the main effect of a particular SNP and a
particular anthropometric measure, respectively, and
β3 is the effect of the interaction term being tested. All of
analyses in each stage were conducted using the R pro-
gram (version 2.15.2; http://www.r-project.org/).
SNPs were selected for replication stage 1 if the SNP’s
main effect P value was less than 1 × 10−4 in the discovery
stage. SNPs that were found to be statistically significant
(PSNP < 0.05) in replication stage 1 were selected for repli-
cation stage 2. To combine association results for selected
SNPs in multiple stages (discovery, replication 1 and repli-
cation 2), we performed inverse variance weighted meta-
analysis for each SNP’s main and interactional effects from
each stage using the rmeta package of the R program in
which fixed effects were assumed.
After meta-analyses, SNPs with the accepted genome-
wide significance level (P < 5 × 10−8), which reflected
testing of one million SNPs [21], were considered statis-
tically significant. The more conservative genome-wide sig-
nificance threshold is P < 3.18 × 10−8 based on Bonferroni
correction, but no SNP in this study exceeded this thresh-
old. It should be noted that we have selected SNPs which
showed the moderate signal (PSNP < 1.0 × 10
−4) in the
discovery stage, expected to be achieved by abundant
genetic variants. This stage would require less correc-
tion for multiple testing than the final stage targeting
at genome-wide significance [22]. From our 3-stage study
design, we have discovered a genetic variation that reached
genome-wide significance in the final stage.
We also performed stratified analyses to identify the
combined effect of BMI and SNP on BP. We tested the
association between BMI and BP in each genotype of
SNP (ex: GG, GA, AA) and the association betweenSNP and BP in each BMI sub-group (BMI < 18.5,
18.5 ≤ BMI < 25, 25 ≤ BMI < 30, BMI ≥ 30).
Prediction of TFBS using ENCODE database
To elucidate the biological meaning of variant, we exam-
ined the cluster scores of transcription factor binding sites
(TFBS) nearby SNP based on data from all five ENCODE
(The Encyclopedia of DNA Elements Consortium) TFBS
ChIP-seq production groups via UCSC Genome Browser
(http://genome.ucsc.edu/). The UCSC Genome Browser
has released a track containing 690 datasets of transcrip-
tion factor ChIP-seq peaks.
Results
Descriptive information of study samples
Table 1 provides the descriptive characteristics of the
12,030 study subjects enlisted for the discovery stage of
our analysis from the Korea Association REsource (KARE)
project of the Korean Genome Epidemiological Study
(KoGES), for replication stage 1 from the Health Examinee
cohort (HEXA) of KoGES, and for replication stage 2 from
Japanese populations enrolled in the Ehime and Amagasaki
studies [8,11,19]. The HEXA group had a higher propor-
tion of women (56.6%) than the KARE group (50.0%), and
the average SBP was higher in the HEXA subjects (121.7 ±
14.4) than in the KARE subjects (119.6 ± 17.4). In contrast,
the average DBP was higher in the KARE subjects (79.3 ±
11.1) than in the HEXA subjects (77.1 ± 9.89). All but one
(weight) of variables in two groups showed statistically sig-
nificant differences (P < 0.0001). The Japanese populations
examined in replication stage 2 tended to be older and to
have higher SBP than the HEXA and KARE groups. The
correlations between BP and anthropometric measures
are summarized in Additional file 1: Table S1. There were
moderate to low correlations between BP and anthropo-
metric measures across the KARE and HEXA subjects
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between two independent correlation coefficients were
statistically significant (Additional file 1: Table S1).
A genome-wide scan including interaction terms
We performed genome-wide association analyses on
SBP and DBP in the 7,486 KARE subjects with consider-
ation of interaction between approximately 1.6 million
SNPs and four obesity-related anthropometric measures
using four linear regression models with the following
interaction terms: SNP × BMI, height, weight, or WHR
(See Figure 1 for the overall study scheme). Genomic
inflation factors (λgc) of each SNP’s main and interactional
effects were calculated for each model. All of the λgc values
were ≤ 1.057 (Additional file 1: Table S2). The quantile-
quantile plots for SBP and DBP in each model with inter-
action terms are presented in Additional file 1: Figure S1.
In discovery stage, we identified several BP associated
genetic loci with moderate significance (PSNP < 1.0 × 10
−4)
including some that had not been detected in previous
BP-associated GWASs which considered only the SNP’s
main effects when analyzed (Additional file 1: Table S3).
To verify these loci in subsequent stage, we selected the
317 SNPs exceeding PSNP < 1.0 × 10
−4 that showed the
most significant signals at each locus considering LinkageFigure 1 Overall study scheme. We carried out a genome-wide scan for
between SNPs and the anthropometric measures BMI, height, weight, and
2), we identified a SNP that was strongly associated with SBP by a linear reDisequilibrium block (LD, r2 > 0.2) for replication stage 1
with 3,703 HEXA subjects, 146 SNPs associated with SBP
only, 150 SNPs associated with DBP only and 21 associ-
ated with both SBP and DBP (Additional file 1: Table S3).
In replication stage 1, we found six SNPs that showed
statistical significance (PSNP < 0.05) in the SNP’s main effect
with the concordant direction in discovery stage’s. These
six SNPs were also tested in Japanese populations (n = 841)
of replication stage 2 (Additional file 1: Table S4).
In inverse variance meta-analyses combining the results
from the three stages for the six SNPs (Additional file 1:
Table S4), there was one SNP that reached genome-wide
significance (P < 5 × 10−8). SNP rs13390641, located in the
intergenic region on 2q12.1 near the transmembrane pro-
tein 182 gene (TMEM182), was found to be associated
with SBP when the interaction between SNP and BMI was
considered in the analyses (combined PSNP = 3.83 × 10
−8
and PINT = 5.28 × 10
−8; Table 2). For rs13390641, there
was no evidence for heterogeneity across the three stages
(heterogeneity P = 0.47; Table 2).
Comparison of the effect of rs13390641 and BMI on BP in
categorized groups
We compared the effect estimates for BMI on BP among
three genotype classes of rs13390641 by linear regressionBP-associated (SBP and DBP) SNPs that included interaction terms
WHR. After the three-stage analysis (discovery, replication 1, replication
gression model that incorporated interaction between SNPs and BMI.
Table 2 SNP with a significant effect on BP when considering interaction between SNP and BMI of the subject
Trait Interaction SNP; cytoband; nearby genes;minor allele/major allele
*Type of
effect
Discovery (n = 7,486) Replication 1 (n = 3,703) Replication 2 (n = 841) Combined (n = 12,030)






−13.9(3.35) 3.51 × 10–5
0.10
−11.6 (4.35) 7.73 × 10–3
0.10
−32.1 (12.5) 1.01 × 10–2 −14.4 (2.62) 3.83 × 10–8 0.47 (2.52)
Interaction 0.56 (0.14) 3.80 × 10–5 0.47 (0.18) 9.39 × 10–3 1.35 (0.54) 1.21 × 10–2 0.59 (0.11) 5.28 × 10–8 0.48 (2.49)
#rs13390641 is an imputed SNP in each stage and the effect allele is A; *Type of effect in a linear regression model with SNP × BMI interaction term; SBP, systolic blood pressure; BMI, body mass index; MAF, minor
allele frequency; Beta, standardized regression coefficient; se, standard error.
A test of heterogeneity (Phet) was conducted; Q, Cochrane’s Q value based on chi-squared statistics.



















Table 3 Effect of BMI on BP by rs13390641 genotype
classes
Trait Genotype n Beta (se) P
SBP GG 8980 0.92 (0.05) 4.62 × 10-66
GA 2051 1.32 (0.11) 5.76 × 10-32
AA 135 1.58 (0.47) 9.68 × 10-4
DBP GG 8980 0.75 (0.04) 7.81 × 10-96
GA 2051 0.99 (0.07) 2.02 × 10-39
AA 135 1.35 (0.31) 3.26 × 10-5
SBP, systolic blood pressure; DBP, diastolic blood pressure; n, sample size of
each subgroup; Beta, standardized regression coefficient; se, standard error.
The association analyses between BP and BMI in each group were performed
using linear regression adjusted by age and sex.
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The strongest effect of BMI was for SBP in subjects
carrying the homozygous A allele of rs13390641 (Beta =
1.58, P = 9.68 × 10−4). In the case of DBP, the effect of
BMI was also highest in subjects carrying the homo-
zygous A allele (Beta = 1.35, P = 3.26 × 10−5; Table 3 and
Figure 2).
We also calculated effect estimates for rs13390641 on
BP in four BMI sub-groups. In the highest BMI sub-group
(BMI ≥ 30), rs13390641 showed a strong increasing effect
on SBP (Beta = 5.35, P = 3.22 × 10−3). For DBP, the effect
of rs13390641 also increased significantly in the highest
BMI sub-group (Beta = 3.50, P = 3.24 × 10−3; Table 4 and
Figure 2). It is enough to say that the subjects in the high-
est BMI sub-group with carrying A allele may have a
higher risk of increasing BP significantly.
Discussion
Few studies have examined the potential interaction
between SNPs and environmental risk factors thatFigure 2 Effect size of BMI and rs13390641 on BP. (a) Effect of BMI on
rs13390641 on SBP and DBP in the four BMI groups. Group 1: BMI < 18.5, G
Data are the mean ± standard deviation.modulate complex traits on a genome-wide scale. The
major strength of our study was that it was able to detect
a previously overlooked BP-associated genetic factor,
rs13390641, with genome-wide significance (P < 5 × 10−8)
because our analyses considered interaction between SNPs
and obesity related anthropometric measures.
The estimated effect of BMI on BP was larger in indi-
viduals carrying two copies of the A allele of rs13390641
than in those carrying two copies of the G allele (Table 3)
and the effect of rs13390641 on BP was larger in obese
individuals (BMI ≥ 30) than in the other subjects (Table 4).
These stratified analyses strongly suggest that the joint
effect of rs13390641 and obesity (BMI) on risk of develop-
ing BP identified that the effect in the obese individuals
carrying risk (A) alleles (GA or AA genotype) was much
higher than that in obese individuals carrying non-risk (G)
alleles.
The rs13390641 SNP is located intergenic region, 602 kb
downstream of the gene that encodes transmembrane pro-
tein 182, which is composed of four putative membrane-
spanning regions [23]. There were low correlation between
variants in TMEM182 and rs13390641 (Pearson’s correl-
ation coefficient, r ≈ 0.10) (Additional file 1: Figure S2). We
also examined LD block between variants in TMEM182
and rs13390641 using Haploview software based on
HapMap release 22, CHB + JPT panel. These variants
located in a same locus, 2q12.1, but were not in a LD
(Additional file 1: Figure S3). However, interestingly, there
were several transcription factor binding sites located
between TMEM182 and rs13390641. Of them, binding
sites for RAD21, CTCF and STAT1 showed the highest
cluster scores that were 767, 500 and 769, respectively
(Visualization in the UCSC Genome Browser, http://
genome.ucsc.edu/). Especially, STAT1 plays a part in
the process of blood circulation (referring to the GeneSBP and DBP in the three rs13390641 genotypes. (b) Effect of
roup 2: 18.5 ≤ BMI < 25, Group 3: 25 ≤ BMI < 30, and Group 4: BMI≥ 30.
Table 4 Effect of rs13390641 on BP by BMI sub-groups
Trait BMI sub-group n Beta (se) P
SBP BMI < 18.5 212 −2.26 (2.18) 0.2993
18.5 ≤ BMI < 25 6700 −0.02 (0.43) 0.9540
25≤ BMI < 30 3850 −0.10 (0.58) 0.8690
30≤ BMI 427 5.35 (1.81) 0.0032
DBP BMI < 18.5 212 −2.34 (1.37) 0.0884
18.5 ≤ BMI < 25 6700 −0.01 (0.29) 0.9600
25≤ BMI < 30 3850 0.06 (0.39) 0.8720
30≤ BMI 427 3.50 (1.18) 0.0032
SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass
index; n, sample size of each subgroup; Beta, standardized regression
coefficient; se, standard error; The association analyses between BP and
rs13390641 in each group were performed using linear regression adjusted by
age and sex.
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TMEM182 and suggests a possible modulation of BP
level.
No phenotypes with a direct functional connection to
TMEM182 have been reported, but its expression in
adipocytes and its potential role in glaucoma have been
explored [23,24]. Elevated levels of the proinflammatory
cytokine TNF-α are associated with obesity [25,26].
TNF-α also regulates the expression of TMEM182 in
white adipose tissue [23]. Taken together, these results
suggest that expression of TMEM182 may be integral to
the adipocyte phenotype mediated by the TNF-α pathway,
and that TMEM182 may act on BP.
Up to date, some studies have discovered genetic
variants associated BP via GWAS using KARE subjects
[27-30]. These studies have identified 8 genes, PARK2,
OPA1, ATP2B1, CSK, ARSG, CSMD1, CYP17A1 and PLE-
KHA7 that located SNPs associated BP or hypertension.
We have tested genetic effects of 22 SNPs on 8 genes for
SBP considered interaction between SNPs and BMI. How-
ever, none of them represented the statistical significance
in this interaction model (Additional file 1: Table S5). It is
due to method of analyses that previous studies conducted
standard analyses which considered only genetic effects, on
the other hand, our analyses considered not only genetic
effects but also interactional effects. According to the
different method, it is natural that the result came out
differently. So, these previously known SNPs associated
BP based on KARE subjects were not to be considered
as candidates for BP in our analyses.
Although we uncovered only a single locus with signifi-
cant genome-wide association with BP, possibly because of
genetic diversity and differences in environmental effects
between populations, this is the first study to examine
genome-wide associations of BP with interacting genetic
and environmental risk factors in East-Asian populations.
Incorporating gene-environment interactions may becritical for discovering genetic determinants of complex
traits such as BP, as these interactions may better explain
the variance of complex traits than direct effects of indi-
vidual genes.Conclusions
In conclusion, this genome-wide screen for BP-associated
genes, which considered interaction between SNPs and
obesity-related anthropometric measures, identified a gen-
etic variant in East-Asian populations near TMEM182
that may influence BP. This study suggests a useful strat-
egy for discovering new genetic contributors of complex
traits, which may work together with environmental fac-
tors to cause human diseases.Additional file
Additional file 1: Figure S1. The quantile - quantile plots for SBP and
DBP in each model with interaction terms in discovery stage. Figure S2.
Pearson’s correlation coefficient (r) between rs13390641 and 206 SNPs
located from TMEM182 to rs13390641 (Chr 2:102744010 – 103402865).
Figure S3. The linkage disequilibrium (LD) block between rs13390641
and SNPs on TMEM182. Table S1. Correlation of BP and anthropometric
measures. Table S2. Genomic inflation factors of analyses in each model
with interaction terms in the discovery stage. Table S3. Results of
genome-wide association analyses in discovery stage. Table S4. Results
of combined meta-analyses for selected 6 SNPs. Table S5. Results of
association analyses for SBP considered interaction between BMI and
known SNPs that were revealed by earlier experiences within the KARE
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